Immunitybio is trading 4.16% up at $7.89, with biotech-sector strength appearing to provide the main tailwind as XBI gains 2.06%.
- No new company-specific announcement was identified for August 25, 2026; the official release page shows no newer catalyst.
- The latest releases were the August 10 vice-chair appointment and August 4 quarterly results.
- Volume was approximately 5.67 million shares versus 6.8 million average volume.